CL2015002479A1 - Composición farmacéutica que comprende unión de la arginina albúmina-vinculante para suspender la focalización del tratamiento del cáncer. - Google Patents

Composición farmacéutica que comprende unión de la arginina albúmina-vinculante para suspender la focalización del tratamiento del cáncer.

Info

Publication number
CL2015002479A1
CL2015002479A1 CL2015002479A CL2015002479A CL2015002479A1 CL 2015002479 A1 CL2015002479 A1 CL 2015002479A1 CL 2015002479 A CL2015002479 A CL 2015002479A CL 2015002479 A CL2015002479 A CL 2015002479A CL 2015002479 A1 CL2015002479 A1 CL 2015002479A1
Authority
CL
Chile
Prior art keywords
binding
suspend
albumin
pharmaceutical composition
cancer treatment
Prior art date
Application number
CL2015002479A
Other languages
English (en)
Inventor
Bing Lou Wong
Sui Yi Kwok
Norman Fung Man Wai
Yun Chung Leung
Original Assignee
Vision Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vision Global Holdings Ltd filed Critical Vision Global Holdings Ltd
Publication of CL2015002479A1 publication Critical patent/CL2015002479A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE PATENTE DE INVENCIÓN ESTA RELACIONADA PRINCIPALMENTE CON UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UNION DE LA ARGININA ALBUMINA-VINCULANTE PARA SUSPENDER LA FOCALIZACION DEL TRATAMIENTO DEL CANCER.
CL2015002479A 2013-03-06 2015-09-04 Composición farmacéutica que comprende unión de la arginina albúmina-vinculante para suspender la focalización del tratamiento del cáncer. CL2015002479A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361773214P 2013-03-06 2013-03-06
US14/197,236 US9255262B2 (en) 2013-03-06 2014-03-05 Albumin-binding arginine deminase and the use thereof

Publications (1)

Publication Number Publication Date
CL2015002479A1 true CL2015002479A1 (es) 2016-05-13

Family

ID=51488086

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002479A CL2015002479A1 (es) 2013-03-06 2015-09-04 Composición farmacéutica que comprende unión de la arginina albúmina-vinculante para suspender la focalización del tratamiento del cáncer.

Country Status (22)

Country Link
US (3) US9255262B2 (es)
EP (1) EP2964761B1 (es)
JP (1) JP6243452B2 (es)
KR (1) KR102139844B1 (es)
CN (1) CN105142663B (es)
AP (1) AP2015008714A0 (es)
AU (1) AU2014225712C1 (es)
BR (1) BR112015021182A2 (es)
CA (1) CA2903152C (es)
CL (1) CL2015002479A1 (es)
EA (1) EA036064B1 (es)
ES (1) ES2909664T3 (es)
HK (1) HK1211979A1 (es)
IL (1) IL240976A (es)
MA (1) MA38376B1 (es)
MX (1) MX2015011578A (es)
MY (1) MY175144A (es)
PH (1) PH12015501995B1 (es)
SA (1) SA515360970B1 (es)
SG (1) SG11201506679QA (es)
TW (1) TWI634212B (es)
WO (1) WO2014138319A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
PE20211760A1 (es) 2013-10-18 2021-09-07 Deutsches Krebsforsch Inhibidores marcados de antigeno prostatico especifico de membrana (psma) que comprenden grupos carboxilicos y una region de enlazador modificada, agentes formadores de imagenes y agentes farmaceuticos que los comprenden
CN105985447B (zh) * 2015-03-02 2019-10-22 四川大学华西医院 一种白蛋白结合型肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
CN104789489B (zh) * 2015-03-09 2018-01-23 武汉远大弘元股份有限公司 一株高产精氨酸脱亚胺酶的蜡样芽孢杆菌及其应用
US20190352365A1 (en) * 2017-01-18 2019-11-21 Savior Lifetec Corporation Expression construct and method for producing proteins of interest
SG11202011838XA (en) * 2018-05-31 2020-12-30 Univ Hong Kong Polytechnic Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities
WO2021041954A2 (en) * 2019-08-28 2021-03-04 The Research Foundation For The State University Of New York Targeted delivery of tumor matrix modifying enzymes
CN111394295B (zh) * 2019-11-06 2023-03-10 上海健康医学院 一种制备固定化精氨酸脱亚胺酶及生产[14/15n]-l-瓜氨酸的方法
CN111518851B (zh) * 2019-11-06 2023-05-23 上海健康医学院 一种固定化酶连续制备[14/15n]-l-瓜氨酸的方法
CN115038460A (zh) * 2019-12-02 2022-09-09 香港理工大学 诱导间歇性禁食和调节自噬的方法
US20230372503A1 (en) * 2020-09-25 2023-11-23 Proabtech Inc. Conjugate of functional polypeptide variant, and use thereof
CN113584054B (zh) * 2021-06-28 2023-04-18 河北远大九孚生物科技有限公司 编码精氨酸脱亚胺酶的dna分子及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2900279B2 (ja) * 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
US5196195A (en) * 1990-03-27 1993-03-23 Cornell Research Foundation, Inc. Use of arginase to control nitric oxide formation
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6180387B1 (en) * 1997-08-11 2001-01-30 Smithkline Beecham Corporation Arginine deiminase
GB9823071D0 (en) * 1998-10-21 1998-12-16 Affibody Technology Ab A method
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP2003531590A (ja) * 2000-04-12 2003-10-28 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US20030157091A1 (en) 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
CA2485169C (en) 2002-05-20 2013-03-26 Joseph C. Mcauliffe Peptide derivatives, and their use for the synthesis of silicon-based composite materials
SI1729795T1 (sl) * 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
CN1292002C (zh) 2004-10-21 2006-12-27 北京双鹭药业股份有限公司 一种精氨酸脱酰酶融合蛋白、其制造方法及应用
BR122013001996B1 (pt) 2005-05-18 2022-02-01 Ablynx N.V. Nanocorpos melhorados contra fator alfa de necrose tumoral
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
KR100934656B1 (ko) 2006-02-06 2009-12-31 엘지전자 주식회사 다중 반송파 시스템에서의 무선 자원 할당 방법
US8334365B2 (en) * 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
EP2046820B1 (en) 2006-08-01 2010-10-20 Pieris AG Muteins of tear lipocalin and methods for obtaining the same
EP2190863B1 (en) * 2007-07-31 2015-09-02 Affibody AB New albumin binding compositions, methods and uses
EP2295560A1 (en) 2009-09-14 2011-03-16 RWTH Aachen University Directed evolution of arginine deiminase for increased activity at physiological pH
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof

Also Published As

Publication number Publication date
SA515360970B1 (ar) 2017-07-20
US20160115468A1 (en) 2016-04-28
CA2903152C (en) 2021-02-09
AU2014225712B2 (en) 2017-04-06
WO2014138319A3 (en) 2014-12-24
HK1211979A1 (en) 2016-06-03
USRE47233E1 (en) 2019-02-12
BR112015021182A2 (pt) 2017-10-10
ES2909664T3 (es) 2022-05-09
JP6243452B2 (ja) 2017-12-06
MA38376B1 (fr) 2019-03-29
PH12015501995A1 (en) 2016-01-11
WO2014138319A8 (en) 2015-01-22
CN105142663B (zh) 2017-12-08
EP2964761A2 (en) 2016-01-13
US9255262B2 (en) 2016-02-09
AP2015008714A0 (en) 2015-09-30
KR102139844B1 (ko) 2020-08-03
AU2014225712C1 (en) 2017-09-28
EP2964761B1 (en) 2022-01-19
KR20150124999A (ko) 2015-11-06
SG11201506679QA (en) 2015-09-29
CA2903152A1 (en) 2014-09-12
MX2015011578A (es) 2016-04-25
EP2964761A4 (en) 2016-07-20
IL240976A (en) 2016-09-29
CN105142663A (zh) 2015-12-09
US9803185B2 (en) 2017-10-31
PH12015501995B1 (en) 2016-01-11
MA38376A1 (fr) 2017-10-31
AU2014225712A1 (en) 2015-09-10
MY175144A (en) 2020-06-10
NZ711234A (en) 2021-01-29
EA036064B1 (ru) 2020-09-22
IL240976A0 (en) 2015-11-30
TWI634212B (zh) 2018-09-01
JP2016514111A (ja) 2016-05-19
TW201520336A (zh) 2015-06-01
US20140255377A1 (en) 2014-09-11
EA201500826A1 (ru) 2015-12-30
WO2014138319A2 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
CL2015002479A1 (es) Composición farmacéutica que comprende unión de la arginina albúmina-vinculante para suspender la focalización del tratamiento del cáncer.
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
CL2015002246A1 (es) Conjugados de anticuerpos drogas.
ECSP15026557A (es) Compuestos y sus métodos de empleo
UY35399A (es) Conjugados de fármacos con anticuerpos
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
CO2017001191A2 (es) Conjugados de fármacos con anticuerpos anti-cdh6
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
BR112016000903A2 (pt) anticorpos
EA201691582A1 (ru) Новые фармацевтические препараты
MX2015014500A (es) Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9.
BR112015023457A2 (pt) sistemas adesivos cationicamente curáveis/ de cianoacrilato de duas partes
BR112013025415A2 (pt) métodos para aumentar eficácia de terapia de câncer de folr1
PE20160753A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
BR112018003178A2 (pt) absorvente feminino com braçadeiras de barreira
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
BR112016007891A2 (pt) uso de inibidores de bromodomínio cbp/ep300 para imunoterapia do câncer
UY35055A (es) Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario
BR112016013116A8 (pt) inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas
UY35054A (es) Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf-r
CR20160227A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
GT201600117A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
CL2016000951A1 (es) Forma cristalina anhidra h de cabazitaxel; proceso de preparación; composición farmacéutica que la comprende; útil para tratar cáncer.